Lucy Scientific Acquires Psilocybin And CBD Therapy Asset From Wesana Health

Lucy Scientific Discovery Inc. LSDI completed its acquisition of Wesana Health Inc.'s SANA-013 assets.

SANA-013 is being developed for the treatment of several mental health and central nervous system related conditions, including major depressive disorder, migraine, episodic cluster headaches, and trigeminal neuralgia. According to the company, this novel combination allows both psilocybin and CBD to act in the brain, while also inducing an anti-inflammatory effect that, together, leads to anti-depressant effects.

Formation of Lucy Discoveries Holdings

Lucy Scientific Discovery also announced the formation of Lucy Discoveries Holdings, a new entity that will serve as a platform for the continued advancement of psychedelic medicine research and development. Lucy Discoveries Holdings will focus on expanding and diversifying Lucy's portfolio of innovative therapies, catering to the unmet needs of patients worldwide.

"We are delighted to finalize the acquisition of Wesana's SANA-013 assets and announce the formation of Lucy Discoveries Holdings," stated Richard Nanula, executive chairman of the board, Lucy Scientific Discovery. "This strategic move significantly enhances our capabilities in the development of psychedelic medicine, reinforcing our commitment to revolutionizing mental health treatments. We are excited about the opportunities ahead and the potential to positively impact the lives of individuals around the world."

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay

Related News

Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More